Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of D-0316 in EGFR-mutant advanced or metastatic non-small cell lung cancer
CTR20190338Phase 2Completed
- Sponsor
- InventisBio
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of befotertinib in non-small cell lung cancer (NSCLC), sponsored by InventisBio. Started Mar 2019; status: completed.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20190338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190338.